REPH
Income statement / Annual
Last year (2023), Recro Pharma, Inc.'s total revenue was $94.64 M,
an increase of 4.90% from the previous year.
In 2023, Recro Pharma, Inc.'s net income was -$13.27 M.
See Recro Pharma, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$94.64 M
|
$90.21 M
|
$75.36 M
|
$66.50 M
|
$99.22 M
|
$77.35 M
|
$71.83 M
|
$69.34 M
|
$51.95 M
|
$0.00
|
| Cost of Revenue |
$76.50 M |
$67.08 M |
$55.54 M |
$54.13 M |
$50.98 M |
$43.16 M |
$38.19 M |
$37.15 M |
$28.05 M |
$0.00 |
| Gross Profit |
$18.14 M |
$23.14 M |
$19.82 M |
$12.37 M |
$48.24 M |
$34.19 M |
$33.64 M |
$32.19 M |
$23.90 M |
$0.00 |
| Gross Profit Ratio |
0.19 |
0.26 |
0.26 |
0.19 |
0.49 |
0.44 |
0.47 |
0.46 |
0.46 |
0 |
| Research and Development
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$39.99 M
|
$33.10 M
|
$33.28 M
|
$12.28 M
|
$7.87 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$19.00
|
$0.00
|
$36.88 M
|
$25.43 M
|
$12.74 M
|
$13.02 M
|
$4.00 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$21.02 M
|
$21.95 M
|
$18.37 M
|
$19.00
|
$19.91 M
|
$36.88 M
|
$25.43 M
|
$12.74 M
|
$13.02 M
|
$4.00 M
|
| Other Expenses |
$687,000.00 |
$67.98 M |
$1.04 M |
$20.71 M |
$22.49 M |
$2.58 M |
$2.58 M |
$2.58 M |
$1.88 M |
$0.00 |
| Operating Expenses |
$21.71 M |
$89.94 M |
$19.41 M |
$20.71 M |
$22.49 M |
$79.45 M |
$61.10 M |
$48.60 M |
$27.18 M |
$11.87 M |
| Cost And Expenses |
$98.21 M |
$157.01 M |
$74.95 M |
$74.84 M |
$73.47 M |
$122.61 M |
$99.30 M |
$85.76 M |
$55.24 M |
$11.87 M |
| Interest Income |
$394,000.00 |
$0.00 |
$0.00 |
$0.00 |
$801,000.00 |
$512,000.00 |
$385,000.00 |
$49,000.00 |
$12,000.00 |
$10,544.00 |
| Interest Expense |
-$9.96 M |
-$14.06 M |
$15.13 M |
$19.16 M |
$19.81 M |
$8.76 M |
$12.03 M |
$5.59 M |
$5.56 M |
$4.27 M |
| Depreciation &
Amortization |
$8.91 M
|
$33.11 M
|
$7.57 M
|
$8.55 M
|
$8.40 M
|
$7.85 M
|
$7.45 M
|
$7.58 M
|
$6.00 M
|
$10,544.00
|
| EBITDA |
-$3.57 M
|
$279,000.00
|
$11.33 M
|
$205,000.00
|
$23.63 M
|
-$45.68 M
|
-$32.48 M
|
-$18.15 M
|
-$954,000.00
|
-$11.86 M
|
| EBITDA Ratio |
-0.04 |
0 |
0.15 |
0 |
0.1 |
-0.59 |
-0.45 |
-0.26 |
-0.02 |
0 |
| Operating Income Ratio
|
-0.04
|
-0.36
|
0.05
|
-0.13
|
0.24
|
-0.7
|
-0.56
|
-0.37
|
-0.13
|
0
|
| Total Other
Income/Expenses Net |
-$9.57 M
|
-$19.06 M
|
-$11.78 M
|
-$19.16 M
|
-$19.01 M
|
-$8.24 M
|
-$11.65 M
|
-$5.54 M
|
-$5.55 M
|
-$4.26 M
|
| Income Before Tax |
-$13.14 M |
-$18.78 M |
-$11.37 M |
-$27.50 M |
$4.63 M |
-$62.29 M |
-$51.96 M |
-$31.31 M |
-$12.52 M |
-$16.13 M |
| Income Before Tax Ratio
|
-0.14
|
-0.21
|
-0.15
|
-0.41
|
0.05
|
-0.81
|
-0.72
|
-0.45
|
-0.24
|
0
|
| Income Tax Expense |
$132,000.00 |
$1.11 M |
$15.13 M |
$0.00 |
$801,000.00 |
$17.44 M |
-$1.88 M |
-$1.11 M |
-$15.55 M |
$0.00 |
| Net Income |
-$13.27 M |
-$19.88 M |
-$26.50 M |
-$27.50 M |
-$18.63 M |
-$79.72 M |
-$50.08 M |
-$30.21 M |
$3.03 M |
-$16.13 M |
| Net Income Ratio |
-0.14 |
-0.22 |
-0.35 |
-0.41 |
-0.19 |
-1.03 |
-0.7 |
-0.44 |
0.06 |
0 |
| EPS |
-0.0001 |
-0.34 |
-0.52 |
-1.16 |
-0.79 |
-3.9 |
-2.63 |
-2.82 |
0.36 |
-2.59 |
| EPS Diluted |
-0.0001 |
-0.34 |
-0.52 |
-1.16 |
-0.79 |
-3.9 |
-2.63 |
-2.82 |
0.35 |
-2.59 |
| Weighted Average Shares
Out |
$95.23 B
|
$57.88 M
|
$51.42 M
|
$23.74 M
|
$23.61 M
|
$20.47 M
|
$19.07 M
|
$10.72 M
|
$8.49 M
|
$6.24 M
|
| Weighted Average Shares
Out Diluted |
$95.23 B
|
$57.88 M
|
$51.42 M
|
$23.74 M
|
$23.61 M
|
$20.47 M
|
$19.07 M
|
$10.72 M
|
$8.75 M
|
$6.24 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
